Kim et al.50also indicated that the MET inhibitor PHA‐665752 showed a synergistic effect in combination with an EGFR inhibitor, erlotinib, in the triple negative breast cancer cell line, MDA‐MB‐468. Here, MET is linked to triple-negative breast carcinoma.